Upcoming Dividend • Jun 10
Upcoming dividend of US$0.31 per share Eligible shareholders must have bought the stock before 17 June 2026. Payment date: 03 July 2026. Payout ratio is a comfortable 36% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of American dividend payers (4.2%). Lower than average of industry peers (2.1%). Reported Earnings • May 14
First quarter 2026 earnings released: EPS: US$0.82 (vs US$0.92 in 1Q 2025) First quarter 2026 results: EPS: US$0.82 (down from US$0.92 in 1Q 2025). Revenue: US$8.72m (down 10% from 1Q 2025). Net income: US$2.60m (down 14% from 1Q 2025). Profit margin: 30% (down from 31% in 1Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 12% per year and the company’s share price has also fallen by 12% per year. Declared Dividend • May 07
First quarter dividend of US$0.31 announced Shareholders will receive a dividend of US$0.31. Ex-date: 17th June 2026 Payment date: 3rd July 2026 Dividend yield will be 1.9%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (36% earnings payout ratio) and cash flows (28% cash payout ratio). The dividend has increased by an average of 1.8% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Earnings per share has grown by 3.0% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Announcement • May 06
Utah Medical Products, Inc. announces Quarterly dividend, payable on July 03, 2026 Utah Medical Products, Inc. announced Quarterly dividend of USD 0.3100 per share payable on July 03, 2026, ex-date on June 17, 2026 and record date on June 17, 2026. Announcement • Apr 03
Utah Medical Products, Inc., Annual General Meeting, May 01, 2026 Utah Medical Products, Inc., Annual General Meeting, May 01, 2026. Location: corporate offices of utmd, 7043 south 300 west, utah, midvale United States Reported Earnings • Mar 30
Full year 2025 earnings released: EPS: US$3.48 (vs US$3.96 in FY 2024) Full year 2025 results: EPS: US$3.48 (down from US$3.96 in FY 2024). Revenue: US$38.5m (down 5.8% from FY 2024). Net income: US$11.3m (down 19% from FY 2024). Profit margin: 29% (down from 34% in FY 2024). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 13% per year. Upcoming Dividend • Mar 10
Upcoming dividend of US$0.31 per share Eligible shareholders must have bought the stock before 17 March 2026. Payment date: 03 April 2026. Payout ratio is a comfortable 35% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of American dividend payers (4.3%). In line with average of industry peers (1.8%). Declared Dividend • Feb 08
Fourth quarter dividend of US$0.31 announced Shareholders will receive a dividend of US$0.31. Ex-date: 17th March 2026 Payment date: 3rd April 2026 Dividend yield will be 2.0%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (35% earnings payout ratio) and cash flows (28% cash payout ratio). The dividend has increased by an average of 1.8% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Earnings per share has grown by 3.7% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Announcement • Feb 06
Utah Medical Products, Inc. announces Quarterly dividend, payable on April 03, 2026 Utah Medical Products, Inc. announced Quarterly dividend of USD 0.3100 per share payable on April 03, 2026, ex-date on March 17, 2026 and record date on March 17, 2026. New Risk • Feb 01
New major risk - Revenue and earnings growth Earnings have declined by 0.09% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Reported Earnings • Feb 01
Full year 2025 earnings released: EPS: US$3.48 (vs US$3.96 in FY 2024) Full year 2025 results: EPS: US$3.48 (down from US$3.96 in FY 2024). Revenue: US$38.5m (down 5.8% from FY 2024). Net income: US$11.3m (down 19% from FY 2024). Profit margin: 29% (down from 34% in FY 2024). Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 13% per year. Upcoming Dividend • Dec 09
Upcoming dividend of US$0.31 per share Eligible shareholders must have bought the stock before 16 December 2025. Payment date: 05 January 2026. Payout ratio is a comfortable 35% and this is well supported by cash flows. Trailing yield: 2.2%. Lower than top quartile of American dividend payers (4.4%). Higher than average of industry peers (1.7%). Declared Dividend • Nov 07
Third quarter dividend increased to US$0.31 Dividend of US$0.31 is 1.6% higher than last year. Ex-date: 16th December 2025 Payment date: 5th January 2026 Dividend yield will be 2.1%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (35% earnings payout ratio) and cash flows (28% cash payout ratio). The dividend has increased by an average of 1.8% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Earnings per share has grown by 2.6% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • Oct 24
Third quarter 2025 earnings released: EPS: US$0.82 (vs US$1.02 in 3Q 2024) Third quarter 2025 results: EPS: US$0.82 (down from US$1.02 in 3Q 2024). Revenue: US$9.81m (down 1.9% from 3Q 2024). Net income: US$2.63m (down 26% from 3Q 2024). Profit margin: 27% (down from 36% in 3Q 2024). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 13% per year. Upcoming Dividend • Sep 10
Upcoming dividend of US$0.30 per share Eligible shareholders must have bought the stock before 17 September 2025. Payment date: 02 October 2025. Payout ratio is a comfortable 32% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of American dividend payers (4.4%). Higher than average of industry peers (1.7%). Declared Dividend • Jul 31
Second quarter dividend of US$0.30 announced Shareholders will receive a dividend of US$0.30. Ex-date: 17th September 2025 Payment date: 2nd October 2025 Dividend yield will be 2.2%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (32% earnings payout ratio) and cash flows (29% cash payout ratio). The dividend has increased by an average of 1.8% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Earnings per share has grown by 2.9% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Announcement • Jul 30
Utah Medical Products, Inc. announces Quarterly dividend, payable on October 02, 2025 Utah Medical Products, Inc. announced Quarterly dividend of USD 0.3050 per share payable on October 02, 2025, ex-date on September 17, 2025 and record date on September 17, 2025. Reported Earnings • Jul 25
Second quarter 2025 earnings released: EPS: US$1.86 (vs US$0.98 in 2Q 2024) Second quarter 2025 results: EPS: US$1.86 (up from US$0.98 in 2Q 2024). Revenue: US$19.7m (up 89% from 2Q 2024). Net income: US$6.09m (up 76% from 2Q 2024). Profit margin: 31% (down from 33% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 14% per year, which means it is performing significantly worse than earnings. Upcoming Dividend • Jun 09
Upcoming dividend of US$0.30 per share Eligible shareholders must have bought the stock before 16 June 2025. Payment date: 03 July 2025. Payout ratio is a comfortable 32% and this is well supported by cash flows. Trailing yield: 2.1%. Lower than top quartile of American dividend payers (4.8%). Higher than average of industry peers (1.7%). Declared Dividend • May 11
First quarter dividend of US$0.30 announced Shareholders will receive a dividend of US$0.30. Ex-date: 16th June 2025 Payment date: 3rd July 2025 Dividend yield will be 2.3%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (32% earnings payout ratio) and cash flows (27% cash payout ratio). The dividend has increased by an average of 2.0% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend. Announcement • May 09
Utah Medical Products, Inc. announces Quarterly dividend, payable on July 03, 2025 Utah Medical Products, Inc. announced Quarterly dividend of USD 0.3050 per share payable on July 03, 2025, ex-date on June 16, 2025 and record date on June 16, 2025. Reported Earnings • Apr 30
First quarter 2025 earnings released: EPS: US$0.92 (vs US$1.09 in 1Q 2024) First quarter 2025 results: EPS: US$0.92 (down from US$1.09 in 1Q 2024). Revenue: US$9.71m (down 14% from 1Q 2024). Net income: US$3.04m (down 23% from 1Q 2024). Profit margin: 31% (down from 35% in 1Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 15% per year, which means it is performing significantly worse than earnings. Announcement • Apr 07
Utah Medical Products, Inc., Annual General Meeting, May 02, 2025 Utah Medical Products, Inc., Annual General Meeting, May 02, 2025. Location: thecorporate offices of utmd, 7043 south 300 west, midvale, utah usa, United States Reported Earnings • Mar 27
Full year 2024 earnings released: EPS: US$3.96 (vs US$4.58 in FY 2023) Full year 2024 results: EPS: US$3.96 (down from US$4.58 in FY 2023). Revenue: US$40.9m (down 19% from FY 2023). Net income: US$13.9m (down 17% from FY 2023). Profit margin: 34% (in line with FY 2023). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Upcoming Dividend • Mar 07
Upcoming dividend of US$0.30 per share Eligible shareholders must have bought the stock before 14 March 2025. Payment date: 03 April 2025. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 2.1%. Lower than top quartile of American dividend payers (4.6%). Higher than average of industry peers (1.6%). Declared Dividend • Feb 06
Fourth quarter dividend of US$0.30 announced Shareholders will receive a dividend of US$0.30. Ex-date: 14th March 2025 Payment date: 3rd April 2025 Dividend yield will be 2.0%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (30% earnings payout ratio) and cash flows (24% cash payout ratio). The dividend has increased by an average of 2.0% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend. Reported Earnings • Jan 29
Full year 2024 earnings released: EPS: US$3.96 (vs US$4.58 in FY 2023) Full year 2024 results: EPS: US$3.96 (down from US$4.58 in FY 2023). Revenue: US$40.9m (down 19% from FY 2023). Net income: US$13.9m (down 17% from FY 2023). Profit margin: 34% (in line with FY 2023). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Declared Dividend • Dec 13
Third quarter dividend increased to US$0.30 Dividend of US$0.30 is 1.7% higher than last year. Ex-date: 16th December 2024 Payment date: 3rd January 2025 Dividend yield will be 1.9%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (28% earnings payout ratio) and cash flows (24% cash payout ratio). The dividend has increased by an average of 2.0% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Earnings per share has grown by 4.0% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Announcement • Nov 05
Utah Medical Products, Inc. Appoints Carrie Leigh to Its Board of Directors Utah Medical Products, Inc. announces that its Board of Directors has appointed Carrie Leigh to its Board of Directors. Ms. Leigh, who was employed in direct sales positions for UTMD from 2004 to 2016, graduated with a B.S. in Communications from Santa Clara University and an MBA from the Northwestern University Kellogg School of Management. As she served in her last position as UTMD's manager of Global Direct End User Sales, the Board believes her robust understanding of the functional and strategic challenges that the Company faces will be integral for achieving future revenue growth. Reported Earnings • Oct 30
Third quarter 2024 earnings released: EPS: US$1.03 (vs US$1.08 in 3Q 2023) Third quarter 2024 results: EPS: US$1.03 (down from US$1.08 in 3Q 2023). Revenue: US$10.0m (down 20% from 3Q 2023). Net income: US$3.56m (down 9.4% from 3Q 2023). Profit margin: 36% (up from 32% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Upcoming Dividend • Sep 13
Upcoming dividend of US$0.30 per share Eligible shareholders must have bought the stock before 20 September 2024. Payment date: 04 October 2024. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of American dividend payers (4.4%). Higher than average of industry peers (1.6%). Declared Dividend • Aug 05
Second quarter dividend of US$0.30 announced Shareholders will receive a dividend of US$0.30. Ex-date: 20th September 2024 Payment date: 4th October 2024 Dividend yield will be 1.8%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (28% earnings payout ratio) and cash flows (21% cash payout ratio). The dividend has increased by an average of 1.8% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend. Reported Earnings • Jul 26
Second quarter 2024 earnings released: EPS: US$0.98 (vs US$1.16 in 2Q 2023) Second quarter 2024 results: EPS: US$0.98 (down from US$1.16 in 2Q 2023). Revenue: US$10.4m (down 19% from 2Q 2023). Net income: US$3.45m (down 18% from 2Q 2023). Profit margin: 33% (in line with 2Q 2023). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Upcoming Dividend • Jun 07
Upcoming dividend of US$0.30 per share Eligible shareholders must have bought the stock before 14 June 2024. Payment date: 05 July 2024. Payout ratio is a comfortable 26% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of American dividend payers (4.7%). In line with average of industry peers (1.8%). Declared Dividend • May 10
First quarter dividend of US$0.30 announced Shareholders will receive a dividend of US$0.30. Ex-date: 14th June 2024 Payment date: 5th July 2024 Dividend yield will be 1.7%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (26% earnings payout ratio) and cash flows (20% cash payout ratio). The dividend has increased by an average of 2.0% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Earnings per share has remained steady over the last 5 years. Unless this trend deteriorates, it should provide adequate earnings cover for the dividend. Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: US$1.09 (vs US$1.16 in 1Q 2023) First quarter 2024 results: EPS: US$1.09 (down from US$1.16 in 1Q 2023). Revenue: US$11.3m (down 9.4% from 1Q 2023). Net income: US$3.96m (down 6.1% from 1Q 2023). Profit margin: 35% (up from 34% in 1Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Announcement • Apr 11
Utah Medical Products, Inc., Annual General Meeting, May 03, 2024 Utah Medical Products, Inc., Annual General Meeting, May 03, 2024, at 12:00 Mountain Standard Time. Location: 7043 South 300 West, Midvale Utah United States Agenda: To elect two directors to serve terms expiring at the 2027 Annual Meeting and until successors are elected and qualified; to ratify the selection of Haynie & Company as the Company's independent public accounting firm for the year ending December 31, 2024; and to hold an advisory vote on the Company's executive compensation program. Reported Earnings • Mar 28
Full year 2023 earnings released: EPS: US$4.58 (vs US$4.53 in FY 2022) Full year 2023 results: EPS: US$4.58 (up from US$4.53 in FY 2022). Revenue: US$50.2m (down 3.9% from FY 2022). Net income: US$16.6m (up 1.0% from FY 2022). Profit margin: 33% (up from 32% in FY 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Upcoming Dividend • Mar 07
Upcoming dividend of US$0.30 per share Eligible shareholders must have bought the stock before 14 March 2024. Payment date: 03 April 2024. Trailing yield: 1.7%. Lower than top quartile of American dividend payers (4.7%). In line with average of industry peers (1.7%). Declared Dividend • Feb 08
Fourth quarter dividend of US$0.30 announced Shareholders will receive a dividend of US$0.30. Ex-date: 14th March 2024 Payment date: 3rd April 2024 Dividend yield will be 1.6%, which is about the same as the industry average. Sustainability & Growth Dividend is well covered by both earnings (26% earnings payout ratio) and cash flows (20% cash payout ratio). The dividend has increased by an average of 2.0% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to decline by 71% to shift the payout ratio to a potentially unsustainable range, which is more than the 1.6% EPS decline seen over the last 5 years. Reported Earnings • Jan 30
Full year 2023 earnings released: EPS: US$4.57 (vs US$4.53 in FY 2022) Full year 2023 results: EPS: US$4.57 (up from US$4.53 in FY 2022). Revenue: US$50.2m (down 3.9% from FY 2022). Net income: US$16.6m (up 1.0% from FY 2022). Profit margin: 33% (up from 32% in FY 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Upcoming Dividend • Dec 07
Upcoming dividend of US$0.30 per share at 1.5% yield Eligible shareholders must have bought the stock before 14 December 2023. Payment date: 03 January 2024. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of American dividend payers (4.8%). Lower than average of industry peers (1.8%). Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: US$1.08 (vs US$1.18 in 3Q 2022) Third quarter 2023 results: EPS: US$1.08 (down from US$1.18 in 3Q 2022). Revenue: US$12.5m (down 3.5% from 3Q 2022). Net income: US$3.94m (down 8.1% from 3Q 2022). Profit margin: 32% (down from 33% in 3Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Upcoming Dividend • Sep 07
Upcoming dividend of US$0.29 per share at 1.3% yield Eligible shareholders must have bought the stock before 14 September 2023. Payment date: 03 October 2023. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 1.3%. Lower than top quartile of American dividend payers (4.9%). Lower than average of industry peers (1.7%). Announcement • Aug 02
Utah Medical Products, Inc. Approves Quarterly Cash Dividend, Payable on October 3, 2023 Utah Medical Products, Inc. announced that its Board of Directors approved a quarterly cash dividend of twenty-nine and one-half cents ($0.295) per share of common stock payable on October 3, 2023 to shareholders of record at the close of business on September 15, 2023. This is a 1.7% increase over the dividend declared in the same quarter of the prior year. Reported Earnings • Jul 25
Second quarter 2023 earnings released: EPS: US$1.15 (vs US$1.13 in 2Q 2022) Second quarter 2023 results: EPS: US$1.15 (up from US$1.13 in 2Q 2022). Revenue: US$12.9m (down 4.2% from 2Q 2022). Net income: US$4.20m (up 2.4% from 2Q 2022). Profit margin: 33% (up from 31% in 2Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions Derivative • Jun 18
Chairman notifies of intention to sell stock Kevin Cornwell intends to sell 10k shares in the next 90 days after lodging an Intent To Sell Form on the 14th of June. If the sale is conducted around the recent share price of US$99.76, it would amount to US$998k. For the year to December 2016, Kevin's total compensation was 19% salary and 81% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2023, Kevin has owned 188.47k shares directly. Company insiders have collectively sold US$87k more than they bought, via options and on-market transactions in the last 12 months. Upcoming Dividend • Jun 08
Upcoming dividend of US$0.29 per share at 1.2% yield Eligible shareholders must have bought the stock before 15 June 2023. Payment date: 06 July 2023. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of American dividend payers (5.0%). Lower than average of industry peers (1.7%). Recent Insider Transactions • May 21
Independent Director recently sold US$65k worth of stock On the 18th of May, Paul Richins sold around 700 shares on-market at roughly US$93.47 per share. This transaction amounted to 3.2% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$124k more than they bought in the last 12 months. Announcement • May 10
Utah Medical Products, Inc. Announces Quarterly Dividend Payable on July 6, 2023 Utah Medical Products, Inc. announced that its Board of Directors approved a quarterly cash dividend of twenty-nine and one-half cents ($0.295) per share of common stock payable on July 6, 2023 to stockholders of record at the close of business on June 16, 2023. This is a 1.7% increase over the dividend declared in the same quarter of the prior year. Reported Earnings • Mar 28
Full year 2022 earnings released Full year 2022 results: Revenue: US$52.3m (up 6.6% from FY 2021). Net income: US$16.5m (up 11% from FY 2021). Profit margin: 32% (up from 30% in FY 2021). The increase in margin was driven by higher revenue. Buying Opportunity • Mar 23
Now 22% undervalued after recent price drop Over the last 90 days, the stock is down 5.0%. The fair value is estimated to be US$116, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.0% over the last 3 years. Earnings per share has grown by 9.1%. Upcoming Dividend • Mar 09
Upcoming dividend of US$0.29 per share at 1.3% yield Eligible shareholders must have bought the stock before 16 March 2023. Payment date: 04 April 2023. Trailing yield: 1.3%. Lower than top quartile of American dividend payers (4.4%). Lower than average of industry peers (1.9%). Announcement • Feb 08
Utah Medical Products, Inc. Approves Quarterly Cash Dividend, Payable on April 4, 2023 Utah Medical Products, Inc. announced that its Board of Directors approved a quarterly cash dividend of twenty-nine and one-half cents ($0.295) per share of common stock payable on April 4, 2023 to shareholders of record at the close of business on March 17, 2023. This is a 1.7% increase over the dividend declared in the same quarter of the prior year. Buying Opportunity • Feb 07
Now 21% undervalued Over the last 90 days, the stock is up 7.6%. The fair value is estimated to be US$116, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.0% over the last 3 years. Earnings per share has grown by 9.1%. Reported Earnings • Feb 02
Full year 2022 earnings released: EPS: US$4.52 (vs US$4.06 in FY 2021) Full year 2022 results: EPS: US$4.52 (up from US$4.06 in FY 2021). Revenue: US$52.3m (up 6.6% from FY 2021). Net income: US$16.5m (up 11% from FY 2021). Profit margin: 32% (up from 30% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Dec 08
Upcoming dividend of US$0.29 per share Eligible shareholders must have bought the stock before 15 December 2022. Payment date: 04 January 2023. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of American dividend payers (4.3%). Lower than average of industry peers (1.8%). Valuation Update With 7 Day Price Move • Dec 06
Investor sentiment improved over the past week After last week's 15% share price gain to US$102, the stock trades at a trailing P/E ratio of 23x. Average trailing P/E is 33x in the Medical Equipment industry in the US. Total returns to shareholders of 4.1% over the past three years. Board Change • Nov 17
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 5 highly experienced directors. Independent Director James Beeson was the last director to join the board, commencing their role in 2007. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Nov 02
Utah Medical Products, Inc. Approves Quarterly Cash Dividend, Payable on January 4, 2023 Utah Medical Products, Inc. announced that its Board of Directors approved a quarterly cash dividend of twenty-nine and one-half cents ($0.295) per share of common stock payable on January 4, 2023 to shareholders of record at the close of business on December 16, 2022. This is a 1.7% increase over the prior regular quarterly cash dividend. Reported Earnings • Oct 26
Third quarter 2022 earnings released: EPS: US$1.18 (vs US$1.15 in 3Q 2021) Third quarter 2022 results: EPS: US$1.18 (up from US$1.15 in 3Q 2021). Revenue: US$13.0m (up 3.0% from 3Q 2021). Net income: US$4.28m (up 1.8% from 3Q 2021). Profit margin: 33% (in line with 3Q 2021). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Upcoming Dividend • Sep 08
Upcoming dividend of US$0.29 per share Eligible shareholders must have bought the stock before 15 September 2022. Payment date: 05 October 2022. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 1.3%. Lower than top quartile of American dividend payers (4.3%). Lower than average of industry peers (1.8%). Reported Earnings • Jul 27
Second quarter 2022 earnings released: EPS: US$1.12 (vs US$0.94 in 2Q 2021) Second quarter 2022 results: EPS: US$1.12 (up from US$0.94 in 2Q 2021). Revenue: US$13.4m (up 6.5% from 2Q 2021). Net income: US$4.10m (up 20% from 2Q 2021). Profit margin: 31% (up from 27% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has fallen by 1% per year. Upcoming Dividend • Jun 09
Upcoming dividend of US$0.29 per share Eligible shareholders must have bought the stock before 16 June 2022. Payment date: 06 July 2022. Payout ratio is a comfortable 21% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of American dividend payers (3.9%). Lower than average of industry peers (1.6%). Recent Insider Transactions • May 12
Independent Director recently sold US$170k worth of stock On the 11th of May, Barbara Payne sold around 2k shares on-market at roughly US$85.20 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$1.2m more than they bought in the last 12 months. Recent Insider Transactions Derivative • May 06
Independent Director notifies of intention to sell stock Barbara Payne intends to sell 2k shares in the next 90 days after lodging an Intent To Sell Form on the 2nd of May. If the sale is conducted around the recent share price of US$86.25, it would amount to US$173k. Since September 2021, Barbara's direct individual holding has decreased from 9.84k shares to 7.34k. Company insiders have collectively sold US$984k more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Apr 28
First quarter 2022 earnings released First quarter 2022 results: Revenue: US$12.3m (up 12% from 1Q 2021). Net income: US$3.53m (up 17% from 1Q 2021). Profit margin: 29% (up from 28% in 1Q 2021). The increase in margin was driven by higher revenue. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 5 highly experienced directors. Independent Director James Beeson was the last director to join the board, commencing their role in 2007. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Apr 16
Utah Medical Products, Inc., Annual General Meeting, May 06, 2022 Utah Medical Products, Inc., Annual General Meeting, May 06, 2022, at 12:00 Mountain Standard Time. Location: corporate offices of UTMD, 7043 South 300 West, Midvale utah United States Agenda: To elect one director to serve a term expiring at the 2025 Annual Meeting and until a successor is elected and qualified; to ratify the selection of Haynie & Company as the company’s independent public accounting firm for the year ending December 31, 2022; and to hold an advisory vote on the company’s executive compensation program. Reported Earnings • Mar 28
Full year 2021 earnings released: EPS: US$4.06 (vs US$2.95 in FY 2020) Full year 2021 results: EPS: US$4.06 (up from US$2.95 in FY 2020). Revenue: US$49.1m (up 16% from FY 2020). Net income: US$14.8m (up 37% from FY 2020). Profit margin: 30% (up from 26% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Upcoming Dividend • Mar 10
Upcoming dividend of US$0.29 per share Eligible shareholders must have bought the stock before 17 March 2022. Payment date: 05 April 2022. Payout ratio is a comfortable 21% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of American dividend payers (3.7%). Lower than average of industry peers (1.5%). Recent Insider Transactions Derivative • Feb 18
Independent Director notifies of intention to sell stock Barbara Payne intends to sell 2k shares in the next 90 days after lodging an Intent To Sell Form on the 11th of February. If the sale is conducted around the recent share price of US$99.66, it would amount to US$199k. Since March 2021, Barbara's direct individual holding has decreased from 11.84k shares to 7.34k. Company insiders have collectively sold US$1.1m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Feb 03
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: US$4.04 (up from US$2.95 in FY 2020). Revenue: US$49.1m (up 16% from FY 2020). Net income: US$14.8m (up 37% from FY 2020). Profit margin: 30% (up from 26% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Dec 21
Investor sentiment deteriorated over the past week After last week's 19% share price decline to US$90.22, the stock trades at a trailing P/E ratio of 23.4x. Average trailing P/E is 45x in the Medical Equipment industry in the US. Total returns to shareholders of 27% over the past three years. Upcoming Dividend • Dec 07
Inaugural dividend of US$2.00 per share Eligible shareholders must have bought the stock before 14 December 2021. Payment date: 29 December 2021. The company is not currently making a profit but it is cash flow positive. The company last paid an ordinary dividend in August 2021. The average dividend yield among industry peers is 1.4%. 